The Use of Therapeutic Nanoparticulate Systems for Treating Atopic Dermatitis

E-ISSN： 1875-6786|14|1|3-16

ISSN： 1573-4137

Source： Current Nanoscience, Vol.14, Iss.1, 2018-01, pp. : 3-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder involvingdefects in epidermal barrier function and abnormal immune response to environmental stimuli. Standardtreatment of AD involves topical application of emollients and anti-inflammatory drugs such ascorticosteroids.Objective: Because of the barrier function defects in AD skin, the topical drug delivery can lead tosystemic drug absorption, thereby eliciting systemic complications. Nanoparticles as the carriers usedfor cutaneous drug delivery provide some benefits over conventional formulations, including enhancedstability, improved epithelium permeability and bioavailability, controlled drug release, skintargeting, and minimal side effects. In recent years, the concept of using nanocarriers as vehicles fordrug delivery to manage AD has attracted increasing attention. Polymeric nanoparticles, lipidnanoparticles, and liposomes are the most extensively studied nanocarriers for the treatment of AD.In this review, we highlight the recent progress on the development of nanosystems for AD treatment.Method: We systematically introduce the concepts and amelioration mechanisms of the nanomedicaltechniques for AD treatment. Different AD animal models for evaluating the efficacy of the therapeuticnanoparticles are described herein.Results: The discrepancy of the nanoparticle skin absorption between healthy skin and AD skin isalso discussed.Conclusion: This review aimed to summarize the evidence for the therapeutic advantages ofnanoparticles over the conventional AD therapy.